康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

已收盘 07-27 16:08:04

82.300

-0.500

-0.60%

最高84.450	最低79.900	成交量190.20万
今开82.950	昨收82.800	日振幅5.50%
总市值246.08亿	流通市值246.08亿	总股本2.99亿
成交额1.56亿	换手率0.64%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":82.3,"timestamp":1785139684005,"preClose":82.8,"halted":0,"volume":1902000,"delay":0,"changeRate":-0.006038647342995169,"floatShares":299000000,"shares":299000000,"eps":-2.213072845189269,"marketStatus":"已收盘","change":-0.5,"latestTime":"07-27 16:08:04","open":82.95,"high":84.45,"low":79.9,"amount":156319287,"amplitude":0.054952,"askPrice":82.35,"askSize":1500,"bidPrice":82.3,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-2.2443571210113165,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785202200000},"marketStatusCode":5,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":82.8,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":1.019938,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"2653145787","title":"康诺亚：重点研发产品CM512拿下突破性治疗认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2653145787","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653145787?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:46","pubTimestamp":1784789160,"startTime":"0","endTime":"0","summary":"7月23日，康诺亚（02162）发布公告，公司重点研发产品CM512（TSLP/IL-13双抗）已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，用于治疗慢性鼻窦炎伴鼻息肉。CM512是公司自主研发的一种重组抗胸腺基质淋巴细胞生成素（TSLP）和抗白介素-13（IL-13）双特异性抗体，为全球首款IgG-like长效型TSLPxIL-13双阻断剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607233818860096.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607233818860096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1574","BK1587","BK1161","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653671165","title":"港股异动 | 康诺亚-B(02162)涨超3% CM512已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2653671165","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653671165?lang=zh_cn&edition=full","pubTime":"2026-07-23 14:15","pubTimestamp":1784787355,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B涨超3%，截至发稿，涨2.03%，报85.3港元，成交额8513.19万港元。消息面上，7月23日午间，康诺亚-B发布公告，公司的重点研发产品CM512已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，用于治疗慢性鼻窦炎伴鼻息肉。截至本公告日期，一项评价CM512注射液在CRSwNP受试者中的安全性和有效性的随机、双盲、安慰剂平行对照II期临床研究正在进行中，试验结果将适时作出公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","VXUS","BK4585","BK1583","BK1574","KCAI","02162","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131916151","title":"港股直击 | 创新药板块走高，康方生物涨近7%，康诺亚-B、荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131916151","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131916151?lang=zh_cn&edition=full","pubTime":"2026-07-23 13:46","pubTimestamp":1784785579,"startTime":"0","endTime":"0","summary":"7月23日，创新药板块走高，康方生物涨近7%，康诺亚-B、荣昌生物涨超3%，恒瑞医药、药明康德涨超2%，药明生物涨近2%。消息面上，康诺亚-B公告称，公司重点研发产品CM512（TSLP/IL-13双抗）已被国家药监局药审中心纳入突破性治疗品种名单，拟用于治疗慢性鼻窦炎伴鼻息肉。CM512为公司自主研发的IgG-like长效型TSLPxIL-13双阻断剂，此前I期临床研究已于2025年11月达成全部研究终点，并于2026年4月在《Journal of Translational Medicine》发表相关结果。目前，CM512用于慢性鼻窦炎伴鼻息肉的II期临床研究正在推进，公司同时布局中重度哮喘、中重度慢阻肺、成人中重度特应性皮炎、慢性自发性荨麻疹等多个适应症。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","02269","09995","01276","02162","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111830332","title":"康诺亚生物CM512获突破性疗法认定，用于慢性鼻窦炎伴鼻息肉治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1111830332","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111830332?lang=zh_cn&edition=full","pubTime":"2026-07-23 12:01","pubTimestamp":1784779272,"startTime":"0","endTime":"0","summary":"康诺亚生物旗下药物CM512，已被纳入针对慢性鼻窦炎伴鼻息肉（CRSwNP）的突破性疗法认定名单。这一认定标志着该候选疗法在满足未满足的临床需求方面取得了重要进展，有望为患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02162","BK1574","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653277829","title":"康诺亚业绩预告扭亏背后：核心产品康悦达半年销售首破3.9亿元，12亿元利润超八成来自一次性资产出售","url":"https://stock-news.laohu8.com/highlight/detail?id=2653277829","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653277829?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:58","pubTimestamp":1784635111,"startTime":"0","endTime":"0","summary":"近日，康诺亚发布2026年半年度业绩预告，公司预计中期净利润不低于12亿元，系出售OuroMedicines股权收益16.8亿元计入所致。值得注意的是，该公司2025年同期亏损约7900万元。据公告披露的利润来源细项，包括不可持续资产出售、主营业务收入、合作收入。其中，资产出售收益16.8亿元，核心产品销售收入3.9亿元，CMG901里程碑付款约2.2亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607213815819095.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213815819095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","02162","BK1161","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653323273","title":"【券商聚焦】国海证券维持康诺亚-B买入评级 指公司历史性扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2653323273","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653323273?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:23","pubTimestamp":1784625794,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国海证券发布研报指，康诺亚-B 发布2026年上半年业绩预告，公司核心产品商业化进入全面提速阶段，并实现历史性扭亏为盈。核心产品康悦达销售收入超过人民币3.9亿元，同比增幅超132%。报告期内，公司预计实现净利润不低于人民币12亿元，对比去年同期约7900万元的亏损，实现历史性扭亏为盈。展望未来，公司预计将持续获得BD收入分成及康悦达销售放量。国海证券维持“买入”评级，预计公司2026/2027/2028年收入分别为12.80/18.45/27.68亿元，对应PS估值16.5/11.4/7.6倍。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986389","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000750","KCE","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652459260","title":"港股异动 | 康诺亚-B(02162.HK)涨近7% 对外合作及商业化销售双轮驱动 预计上半年扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2652459260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652459260?lang=zh_cn&edition=full","pubTime":"2026-07-20 14:42","pubTimestamp":1784529779,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02162","BK1161","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162098983","title":"港股直击 | 生物医药股板块走强，荣昌生物、药明合联、康诺亚涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162098983","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162098983?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:22","pubTimestamp":1784517729,"startTime":"0","endTime":"0","summary":"7月20日，生物医药股板块走强，荣昌生物、药明合联、康诺亚涨近8%，君实生物涨近7%，康方生物涨近6%，药明生物涨近5%。消息面上，创新药板块近期迎来多重催化。一方面，政策端持续释放支持信号，国务院发布《国民健康“十五五”规划》，提出加强创新药和医疗器械全链条支持，优化创新药及临床急需药品审评审批机制，进一步完善创新药发展环境。另一方面，国产创新药商业化和海外授权进展持续受到关注，工信部数据显示，今年上半年共有38款创新药获批上市，其中国产创新药占比超过80%。随着下半年全球医学会议密集召开，包括WCLC、ESMO、ASH等重要学术会议，部分创新药企业核心管线的临床数据将陆续披露，市场关注重点重新回到研发进展和商业化兑现能力。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","02513","09926","02162","09995","02269","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186797751","title":"异动解读｜康诺亚-B盘中上涨7.1%，盈喜叠加创新药板块资金共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1186797751","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186797751?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:35","pubTimestamp":1784514915,"startTime":"0","endTime":"0","summary":"7月20日，康诺亚-B盘中上涨7.1%，报87.45港元，成交额5078.37万港元。消息面上，创新药板块今日集体活跃，多支头部公募密集触及港股创新药举牌线，板块资金共振明显。核心产品康悦达上半年收入超3.9亿元，同比增长超132%。多重利好叠加板块情绪催化，共同推动股价走强。康诺亚生物医药科技有限公司专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法，核心产品覆盖特应性皮炎、哮喘、慢性鼻窦炎伴鼻息肉等适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652269822","title":"创新药板块活跃 荣昌生物(09995)涨7.28% 多支头部公募大举举牌港股创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2652269822","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652269822?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:26","pubTimestamp":1784514372,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块活跃，荣昌生物 涨7.28%，歌礼制药-B涨6.81%，科伦博泰生物涨6.70%，康诺亚-B涨6.25%，康方生物涨5.83%，药明合联涨5.53%，石药集团涨4.94%，三生制药涨5.02%，信达生物涨4.55%，药明生物涨4.60%，恒瑞医药涨4.00%，百济神州涨3.88%。头部机构密集触及举牌线，凸显对创新药板块的看好。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986240","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","06978","IE00BZ08YT58.USD","LU0052750758.USD","LU1226288170.HKD","01276","LU0516423174.USD","BK1588","01093","LU1242518931.SGD","LU0708995583.HKD","LU1242518857.USD","HK0000165453.HKD","LU0348827113.USD","01672","SG9999002463.SGD","09995","LU1720050803.USD","LU1951186391.HKD","01530","09926","KCAI","LU0327786744.USD","LU0196878994.USD","LU0359201612.USD","LU0516422440.USD","LU0516422366.SGD","06160","BK1593","LU2328871848.SGD","VXUS","LU0417516738.SGD","BK4585","LU2097828474.EUR","IBBQ","159992","LU2399975544.HKD","LU0043850808.USD","01801","BK0239","LU1064130708.USD","LU0979878070.USD","KURE","688331","02162","02269","02268","BK1576","LU0348735423.USD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129825600","title":"异动解读｜康诺亚-B盘中下跌5.12%，生物科技板块整体走弱叠加前期利好兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=1129825600","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129825600?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:21","pubTimestamp":1784254864,"startTime":"0","endTime":"0","summary":"7月17日，康诺亚-B盘中下跌5.12%，报82.55港元，成交额6347.34万港元。公司所在生物科技板块全线走弱，三生制药跌9.49%、康方生物跌9.38%、科伦博泰生物跌4.73%、信达生物跌3.5%、百济神州跌2.2%，行业整体承压明显。同日CM512双抗拟纳入突破性治疗。7月16日高盛增持28.75万股，持股比例升至5.00%。本次下跌背景为前期多重利好已陆续释放后，叠加板块集体回调。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651281394","title":"康诺亚-B(02162.HK)获The Goldman Sachs Group, Inc.增持28.75万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651281394","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651281394?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:37","pubTimestamp":1784212622,"startTime":"0","endTime":"0","summary":"格隆汇7月16日丨根据联交所最新权益披露资料显示，2026年7月13日，康诺亚-B(02162.HK)获The Goldman Sachs Group, Inc.在场内以每股均价81.1877港元增持好仓28.75万股，涉资约2334.15万港元。\r\n\r\n　　增持后，The Goldman Sachs Group, Inc.最新持好仓数目为1494.38万股，持好仓比例由4.91%上升至5.00%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202607/16/20260716188669.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202607/16/20260716188669.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260716/32309854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2237443465.HKD","BK1587","LU1868836591.USD","LU0096364046.USD","BK4516","LU2237438978.USD","LU1804176565.USD","LU0345770308.USD","IE0004086264.USD","GSX","IE0004091025.USD","BK4585","BK4588","IE00BSNM7G36.USD","LU2237443382.USD","LU0345770993.USD","LU0742534661.SGD","LU2237443549.SGD","BK1574","IE0034235188.USD","LU2471134523.USD","BK1583","02162","LU1868837300.USD","LU1868837136.USD","LU2471134952.CNY","LU2750360641.GBP","LU2237443622.USD","LU0251142724.SGD","BK4127","LU2265009873.SGD","BK4504","BK4550","IE00B19Z3581.USD","LU1894683348.USD","LU0106831901.USD","BK4533","LU0048573561.USD","LU0251131958.USD","LU0942090050.USD","LU0061475181.USD","LU2471134796.USD","IE0002270589.USD","LU1668664300.SGD","BK4552","IE00BFXG1179.USD","LU2237443978.SGD","LU1868836914.USD","LU0868494708.USD","LU2750360997.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651464715","title":"康诺亚-B(02162.HK)盈喜：预期中期利润不低于12亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2651464715","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651464715?lang=zh_cn&edition=full","pubTime":"2026-07-15 23:17","pubTimestamp":1784128622,"startTime":"0","endTime":"0","summary":"格隆汇7月15日丨康诺亚-B公告，于2026年上半年，公司产品康悦达?收入录得超过人民币3.9亿元，同比增长超过132%。截至2026年6月30日止，本公司商业化团队规模已逾500人，覆盖超过1,600家医院和260多个城市，市场准入工作快速推进。　　根据集团截至2026年6月30日止6个月的未经审核综合管理帐目及董事会目前可得资料的初步评估，预期集团于报告期内将录得利润不低于人民币12亿元，而上年同期亏损约为人民币7900万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260715/32308746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1583","BK1587","BK1574","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184111232","title":"康诺亚-B发布正面盈利预告：预计2026年上半年净利不少于12亿元，核心产品收入同比增132%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184111232","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184111232?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:42","pubTimestamp":1784126540,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司7月15日公告称，公司预计截至2026年6月30日止六个月将实现不少于人民币12亿元的利润，而上年同期则录得约人民币79百万元的亏损。本次盈利预告基于截至2026年6月30日止未经过审计的管理账目编制，相关数据仍有待外部审计师审核。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651461228","title":"康诺亚-B(02162.HK)发盈喜 预期上半年业绩同比扭亏为盈至不低于12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651461228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651461228?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:41","pubTimestamp":1784126516,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","BK1574","02162","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651430779","title":"港股异动 | 康诺亚-B(02162)盘中涨超9% TSLP/IL-13双抗CM512拟纳入突破性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2651430779","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651430779?lang=zh_cn&edition=full","pubTime":"2026-07-15 15:28","pubTimestamp":1784100516,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B盘中涨超9%，截至发稿，涨6.69%，报86.15港元，成交额4.68亿港元。消息面上，7月15日，康诺亚TSLP/IL-13双抗CM512拟纳入突破性治疗，用于治疗慢性鼻窦炎伴鼻息肉。目前CM512针对慢性鼻窦炎伴鼻息肉的II期临床研究已完成患者入组，同时还在推进特应性皮炎、哮喘、慢阻肺、慢性自发性荨麻疹等多个适应症的临床研究，布局广阔。本次拟纳入突破性治疗品种，将加速CM512后续审评审批进程，缩短上市周期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1587","BK1574","BK4588","VXUS","KCAI","BK1583","02162","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0348827113.USD","01801","LU0502904849.HKD","01530","LU0561508036.HKD","06855","LU1720050803.USD","IE00BPRC5H50.USD","06978","02268","LU0417516738.SGD","09995","BK1593","LU2476274308.USD","LU2097828474.EUR","BK1574","LU0417516902.SGD","09926","MEDX","LU0417516571.SGD","LU2778985437.USD","BK1589","LU0348767384.USD","IBBQ","06990","LU0540923850.HKD","BK1161","LU2097828631.EUR","02157","LU2399975544.HKD","IE00B543WZ88.USD","BK1587","159992","LU0348784397.USD","LU0348825331.USD","LU0455707207.USD","KURE","BK1141","BK1583","LU2097828557.USD","LU2097828714.EUR","BK1191","02162","LU0634319403.HKD","SG9999014674.SGD","LU2328871848.SGD","01477","LU2488822045.USD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107760169","title":"异动解读｜康诺亚-B盘中上涨5.08%，核心产品入选新版基药目录叠加多家券商维持买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1107760169","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107760169?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:49","pubTimestamp":1784080187,"startTime":"0","endTime":"0","summary":"7月15日，康诺亚-B盘中上涨5.08%，报85.1港元，成交额6893.28万港元。此外，近日华源证券、国泰海通证券、国信证券等多家机构密集发布研报，维持或首予买入评级，指出公司商业化放量与BD收益兑现共振，吉利德收购Ouro Medicines已带来2.57亿美元首付款入账，后续里程碑付款空间可观。同日生物科技板块整体走强，科伦博泰生物涨9.8%，信达生物涨5.94%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651787480","title":"【券商聚焦】交银国际：新版基药目录落地 荣昌、先声、康诺亚关键品种有望迎放量机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2651787480","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651787480?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:14","pubTimestamp":1784078047,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，新版基药目录落地，重点聚焦创新药、慢病药和儿童药：本次新增116个品种均为现行医保目录内药品。据测算，新版基药目录药品占全国公立医疗卫生机构药品配备品种使用总量的71%，其中基层/二级/三级医疗机构占比分别为78%/74%/65%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWQ0NzJkZTcxMzM4ODY4MjA2MzM0OTUz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985881","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","BK1515","IE00B031HY20.USD","LU1813983027.USD","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1226288170.HKD","IE0008369823.USD","KCE","HK0000165453.HKD","BK1583","LU1008478684.HKD","03329","IE00BZ08YS42.EUR","BK1521","BK1587","IE0008368742.USD","LU0314109678.HKD","LU1993786604.SGD","LU2039709279.SGD","LU1152091754.HKD","BK1574","LU1226288253.USD","02096","LU1969619763.USD","LU1226287875.USD","LU1226287792.SGD","LU0501845795.SGD","BK1191","BK1147","LU1226287529.USD","LU0140636845.USD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU1807302812.USD","LU1328277881.USD","LU1152091168.USD","09995","LU0326950275.SGD","IE00B543WZ88.USD","LU1951186391.HKD","LU0067412154.USD","LU0072913022.USD","01093","LU1960683339.HKD","LU2328871848.SGD","KURE","LU0315179316.USD","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907376","title":"【券商聚焦】华源证券维持康诺亚-B(02162)买入评级 指商业化与BD共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907376?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:39","pubTimestamp":1783665555,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华源证券发布研报指，康诺亚-B 正迈入商业化放量与BD收益兑现的共振阶段，2026年下半年多项关键催化剂值得期待。首先，CMG901若于2026年下半年向美国FDA申报并于2027年进入商业化，公司将在收到6300万美元首付款的基础上，逐步兑现总额超11亿美元的潜在里程碑及销售分成，持续增厚业绩。华源证券预计公司2026-2028年归母净利润分别为11.67/0.59/5.50亿元。考虑到公司商业化放量可期，伴随着商业化进程持续推进，BD收益有望逐步兑现，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985582","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BD","KCE","161027","02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0141},{"period":"1month","weight":0.3574},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.4539},{"period":"1year","weight":0.3431},{"period":"ytd","weight":0.5491}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.139787},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}